Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EmLina Renal: Empagliflozin vs Linagliptin in Renal Transplant Recipients
NCT06098625Not yet recruiting
- Sponsor
- Medanta
- Start
- Nov 2023
- Primary completion
- Jul 2025
- Modality
- Small Molecules
01
Overview
Randomised, open-label trial of empagliflozin in type 2 diabetes mellitus (T2DM) and post-transplantation diabetes mellitus (PTDM) (2 arms), sponsored by Medanta. Primary endpoints: Change in estimated glomerular filtration rate at 12 months, Change in spot urine albumin-creatinine ratio at 12 months and 1 more. Planned start Nov 2023; status: not yet recruiting.
02
Drugs
empagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)post-transplantation diabetes mellitus (PTDM)
Beyond the preview
Go deeper on NCT06098625.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06098625.